A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

Inclusion Criteria: * Healthy, adult, male or female subjects, 18-45 years of age, inclusive, at the screening visit. * Body mass index (BMI) ≥ 18.5 and ≤29.9 kg/m2 at the screening visit. * Continuous non-smoker who has not used nicotine- or tobacco-containing products for at least 3 months prior to first dosing. Exclusion Criteria: * Sustained supine systolic blood pressure ≥130 mmHg or \<90 mmHg, supine diastolic blood pressure ≥80 mmHg or \<50 mmHg at screening or first check-in. * History or presence of clinically significant ECG findings in the opinion of the Principal Investigator (PI) or designee at the screening visit or first check-in, including each of the following: * HR \<45 bpm or \>100 bpm. * QTcF is ≥450 msec (males) or ≥460 msec (females). * QRS ≥110 msec; if ≥110 msec, result will be confirmed by a manual over read. * PR ≥200 msec. * History or presence of: * Risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, family history of Long QT syndrome, Brugada syndrome, or sudden cardiac death). * Sick sinus syndrome, second- or third-degree atrioventricular block, myocardial infarction, angina, pulmonary congestion, symptomatic or significant cardiac arrhythmia, or clinically significant conduction abnormalities. * Clinically significant abnormal laboratory assessments including hypokalemia, hypercalcemia, or hypomagnesemia, in the opinion of the PI or designee.